Brief: Simcere Pharmaceutical Says Marketing Application Of New Indication Of Cosela Accepted By NMPA
14/08/2023 14:00
Aug 14 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* MARKETING APPLICATION OF NEW INDICATION OF COSELA
(TRILACICLIB
HYDROCHLORIDE FOR INJECTION) ACCEPTED BY NMPA
Further company coverage: 2096.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660